Aztreonam L-lysine and methods for the preparation thereof

Abstract

The present invention relates to the L-lysine salt of aztreonam and methods for making the L-lysine salt of aztreonam.

Description

FIELD OF THE INVENTION

The present invention relates to the L-lysine salt of aztreonam and methods for making the L-lysine salt of aztreonam.

BACKGROUND OF THE INVENTION

Aztreonam is a monobactam antibiotic disclosed in U.S. Pat. No. 4,775,670, which is incorporated by reference herein in its entirety. Aztreonam has the chemical name (Z)-2-[[[(2-amino-4-thiazolyl)[[(2S,3 S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl ]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid. Aztreonam is also known as [3S-[3α(Z),4β]]-3-[-[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidinesulfonic acid and (2S,3S)-3-[[2-[2-amino-4-thiazolyl]-(Z)-2-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidine-1-sulfonic acid. Aztreonam has the structure:

U.S. Pat. No. 4,775,670 discloses a process for making Aztreonam and pharmaceutically acceptable salts thereof. However, U.S. Pat. No. 4,775,670 does not teach how to prepare salts of Aztreonam with amines or amino acids.

Applicants encountered unexpected difficulties when trying to prepare salts of Aztreonam with amines and amino acids by dissolution of the acid and base in a solvent and precipitation of the salt. In the majority of experiments an oil, which was impossible to crystallize and which decomposed very rapidly, was obtained.

Applicants have discovered methods that enable the preparation of a solid, stable Aztreonam L-lysine salt.

SUMMARY OF THE INVENTION

The invention relates to an amorphous, solid Aztreonam L-lysine salt. The invention also relates to methods for making the amorphous L-lysine salt. The first method comprises freeze-drying an aqueous solution of Aztreonam L-lysine. The second method comprises spray-drying an aqueous solution of Aztreonam L-lysine. The third method comprises precipitating Aztreonam L-lysine from an aqueous solution.

DETAILED DESCRIPTION OF THE INVENTION

Aztreonam is converted into its L-lysine salt in aqueous solution. The pH plays an important role in the stability of the Aztreonam L-lysine aqueous solution and it should not be more than 5.5. The salt may be isolated from the aqueous solution as an amorphous solid by three different techniques. The three techniques include freeze-drying, spray-drying and precipitation in an organic solvent. All three techniques provide an amorphous product.

Aztreonam L-lysine salt may be obtained by freeze drying an aqueous solution of aztreonam L-lysine. The ratio of Aztreonam and L-lysine used to form the aqueous solution is preferably between 1:1 and 1:2.1. The product obtained by this method appears as white to yellowish flakes and contains about 3 to about 6% water.

Aztreonam L-lysine may also be obtained by spray drying an aqueous solution of Aztreonam L-lysine. The Aztreonam L-lysine salt obtained by spraying is a white to off-white powder. The water content of the product obtained by this method is between about 4 to about 7%. The preferred spray drying parameters are listed in the following table. The parameters apply to a Buchi laboratory spray-drier B-191 (Aspirator rate: 31.5 m³/h).

	Inlet		Concentration	Outlet
Pump speed	temperature	Spray flow	of solution	temperature*
(ml/h)	(° C.)	(l/h)	(m/m %)	(° C.)
240 . . . 750	115 . . . 195	400 . . . 800	7 . . . 29	45 . . . 127
*The outlet temperature depends mainly on the pump speed, inlet temperature, spray flow and concentration of solution.

Using optimal drying parameters, the product exhibited good handling properties, i.e., it was free-flowing. The particle size can also be influenced by regulating the specific drying parameters.

The L-lysine salt of aztreonam can also be isolated by precipitating Aztreonam L-lysine from an aqueous solution. The aqueous solution of aztreonam L-lysine is preferably dropped into an aqueous or anhydrous organic solvent, e.g., ethanol, acetone, etc. The water content of the alcohol used for the precipitation is preferably between about 0 and 9% (m/m).

The Aztreonam L-lysine obtained using these methods was stable in the sense that during 3 months at 2-8° C.:

1. the assay of Aztreonam was maintained constant in the limit 60-66%; and

2. no impurity exceed 0.3 area %.

EXAMPLES

The impurity content of Aztreonam lysine salt using the HPLC method is determined as follows:

a. Aztreonam Lysine salt sample is dissolved in 0.02 M KH₂PO₄ buffer solution (pH adjusted 2.0 with 25 w/w % phosphoric acid) diluent,

b. The sample solution (ca. 10 μl) is injected into a 100.0 mm×4.0 mm, 3 μm RP-1 8 HPLC column,

c. Gradient eluting with a mixture of 0.02 M KH₂PO₄ buffer solution (pH adjusted 3.0 with 25 w/w % phosphoric acid) (A) and acetonitrile (B) according to the following profile:

	Flow rate	Time	Eluent A	Eluent B
	[ml/min]	[min]	[v/v %]	[v/v %]
	1.2	0.0	100.0	0.0
	1.2	16.0	84.0	16.0
	1.2	25.0	70.0	30.0
	1.2	25.1	100.0	0.0
	1.2	30.0	100.0	0

d. The amounts of each impurity was measured at 230 nm wavelength with a UV detector and appropriate recording device.

e. The amount of each impurity was calculated referring to an Aztreonam working standard at a concentration of 2.5 g/ml.

In the above method, Aztreonam has a retention time of about 10.2 minutes.

The assay of Aztreonam Lysine salt using the HPLC method was determined as follows:

a. Dissolving Aztreonam Lysine salt sample in a mixture of 0.02 M KH₂PO₄ buffer solution (pH adjusted 3.0 with 25 w/w % phosphoric acid) and methanol (80:20) diluent,

b. Injecting the sample solution (ca. 10 μl) into a 50.0 mm×4.6 mm, 3 μm RP-18 HPLC column,

c. Isocratic eluting at 1.5 ml/min with a mixture of 0.02 M KH₂PO₄ buffer solution (pH adjusted 3.0 with 25 w/w % phosphoric acid) and methanol in a 83:17 v/v % ratio.

d. Measuring of the amounts of each impurity at 270 nm wavelength with a UV detector and appropriate recording device.

e. Calculating of the assay referring to the Aztreonam working standard at a concentration of 100 [g/ml.

In the above method, Aztreonam has a retention time of about 2.3 minutes

Example 1

Aztreonam (5.00 g, water content: 12.2%) was suspended in 25 ml distilled water at 0-5° C. A solution of 2.70 g L-lysine in 13.5 ml distilled water was added dropwise to the above suspension with cooling (ice-water bath). The solution of Aztreonam L-lysine salt obtained by this method was filtered on a glass filter and freeze dryed.

Product: white flakes.

Yield: 6.8 g (quant.)

Example 2

Aztreonam (35.0 g, water content: 12.6%) was suspended in 230 ml distilled water at 0-5° C. A solution of 17.5 g L-lysine in 45 ml distilled water was added dropwise to the above suspension with cooling (ice-water bath). The solution of Aztreonam L-lysine salt obtained by this method was decolorized with charcoal, filtered on a glass filter and spray dryed using laboratory spray dryer Buchi B-191.

Product: white powder.

Yield: 31 g (62%)

The Aztreonam L-lysine salt produced according to this example, does not contain any impurity exceeding 0.3 area %, and/or maintains at least about 63 weight % of the Aztreonam, after storage for three months at about 2-8° C.

Example 3

Aztreonam (3.50 g, water content: 11.3%) was suspended in 8 ml distilled water at 0-5° C. A solution of 1.80 g L-lysine in 3.5 ml distilled water was added dropwise to the above suspension with cooling (ice-water bath). The solution of Aztreonam L-lysine salt obtained by this method was diluted with 23 ml ethanol and added dropwise to the stirred mixture of 60 ml ethanol and 4.75 ml water at 0-5° C. in 15 min. 120 ml pure ethanol was added dropwise together with the Aztreonam L-lysine salt solution but from another dropping funnel in the same time period. The precipitation was filtered off and dried in air-circulated oven at 38° C.

Product: white powder.

Yield: 3.86 g (77%)

Having thus described the invention with reference to particular preferred embodiments and illustrated it with examples, those of skill in the art may appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification.

Claims

1. An amorphous Aztreonam L-lysine salt, wherein an aqueous solution of the amorphous Aztreonam L-lysine salt has a pH of not more than about 5.5 and the ratio of Aztreonam to L-lysine used to form the aqueous solution is between about 1:1 and about 1:2.1.

2. The amorphous Aztreonam L-lysine salt of claim 1, having a water contentof about 3 to about 7 percent water by weight.

3. The amorphous Aztreonam L-lysine salt of claim 1, which, after storage for three months at about 20° to about 8° C., does not contain any impurity exceeding about 0.3%.

4. The amorphous Aztreonam L-lysine salt of claim 1, which, after storage for three months at about 2° to about 8° C., maintains at least about 60 to about 66 weight percent of Aztreonam.

5. The amorphous Aztreonam L-lysine salt of claim 4, which, after storage for three months at about 2° to about 8° C., maintains at least about 63 weight % of Aztreonam.

6. A method for determining a level of impurities in an amorphous Aztreonam Lysine salt, the method comprising: forming a sample solution comprising the Aztreonam Lysine salt according to claim 1 in a first monobasic phosphate buffer solution at an initial pH; injecting a sample of the Aztreonam Lysine salt solution into a HPLC column; eluting the injected sample with a mixture comprising a second monobasic phosphate buffer solution; and determining an amount of at least one impurity.

7. The method according to claim 6, wherein the injected sample is gradient eluted.

8. The method according to claim 7, wherein; the Aztreonam Lysine salt sample is dissolved in a KH2PO4 buffer solution, having a concentration of about 0.02 M and a pH adjusted to about 2 with about 25 weight percent phosphoric acid; the injected sample is eluted with a mixture of a KH2PO4 buffer solution (A) and acetonitrile (B), wherein the buffer solution (A) has a concentration of about 0.02 M and a pH adjusted to about 3 with about 25 weight percent phosphoric acid; the amount of the at least one impurity is measured at a wavelength of about 230 nm with a UV detector; and the amount of the impurity is determined by reference to an Aztreonam working standard at a concentration of about 2.5 g/ml.

9. The method according to claim 7, wherein: initially, the sample is eluted with an eluent comprising about 100 percent by volume of an eluent (A), wherein the eluent (A) comprises a KH2PO4 buffer solution, having a concentration of about 0.02 M and a pH adjusted to about 3 with about 25 weight percent phosphoric acid; during a first time period, the amount of eluent (A) is reduced, and an amount of an acetonitrile eluent (B) is added to the eluent; during a second time period, the amount of eluent (A) is further reduced, and the amount of eluent (B) is increased; and during a third period of time, the amount of eluent (A) is increased to about 100 percent by volume, and the amount of eluent (B) is reduced to about 0 percent by volume.

10. The method according to claim 6, wherein; the injected sample is isocratic eluted.

11. The method according to claim 10, wherein; the Aztreonam Lysine salt sample is dissolved in a mixture of a KH2PO4 buffer solution, having a concentration of about 0.02 M and a pH adjusted to about 3 with about 25 weight percent phosphoric acid, and methanol; the injected sample is eluted at about 1.5 ml/min with a mixture of a KH2PO4 buffer solution, having a concentration of about 0.02 M and a pH adjusted to about 3 with about 25 weight percent phosphoric acid, and methanol in a volume ratio of about 83:17; the amount of the at least one impurity is measured at about 270 nm wavelength with a UV detector; and the amount of the impurity is determined by reference to an Aztreonam working standard at a concentration of about 100 μg/ml.

12. The amorphous Aztreonam L-lysine salt of claim 1, which is stable for at least three months when stored at about 2° to about 8° Celsius.